“FLOW Trial: Semaglutide and 24% Fewer Kidney Events The First Dedicated GLP-1 Kidney-Outcomes Trial in Type 2 Diabetes and CKD”. Diabzen 4, no. 20 (July 7, 2026): 40–41. Accessed September 17, 2026. https://www.thediabzen.com/index.php/d/article/view/63.